FIELD: biotechnology.
SUBSTANCE: antibody is proposed that binds an extracellular domain of human polypeptide of human SIRP-α. The antibody is capable of binding with extracellular domains v1 and v2 of SIRP-α polypeptide. Conjugates, polynucleotide, an expression vector, and a host cell related to the specified antibody are also proposed. In addition, the invention relates to methods for the treatment or slowing down the progression of cancer, autoimmune disease or inflammatory disease.
EFFECT: invention allows for the effective induction of phagocytosis of tumor cells by macrophages, activation of dendritic cells and inhibition of tumor growth in vivo, when treating with anti-SIRP-α antibodies.
59 cl, 86 dwg, 31 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| STRUCTURES HAVING SIRP-ALPHA DOMAIN OR ITS VERSION | 2016 |
|
RU2740672C2 |
| MULTI-SPECIFIC ANTIGEN-BINDING MOLECULE HAVING SUBSTITUTE FUNCTIONAL ACTIVITY OF BLOOD COAGULATING FACTOR VIII CO-FACTOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SPECIFIED MOLECULE AS ACTIVE INGREDIENT | 2018 |
|
RU2812909C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES AND METHODS OF THEIR USE | 2019 |
|
RU2800779C2 |
| ANTIBODIES TO DENGUE VIRUS, POLYPEPTIDES CONTAINING FC-REGION OPTIONS AND THEIR APPLICATION METHODS | 2017 |
|
RU2758596C2 |
| ANTIBODIES TO DENGUE VIRUS WITH CROSS-REACTIVITY WITH ZIKA VIRUS | 2019 |
|
RU2811697C2 |
| BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO PD1 AND LAG3 | 2018 |
|
RU2778805C2 |
| C5 ANTIBODIES AND THEIR APPLICATION METHODS | 2015 |
|
RU2746356C2 |
| COMBINATION THERAPY BASED ON T-CELL-ACTIVATING BISPECIFIC ANTIGEN-BINDING MOLECULES AGAINST CD3 AND FOLATE RECEPTOR 1 (FOLR1) AND ANTAGONISTS BINDING TO PD-1 AXIS | 2015 |
|
RU2753902C2 |
| ANTIBODIES TO MYOSTATIN, POLYPEPTIDES CONTAINING FC-REGION VARIANTS, AND THEIR APPLICATION METHODS | 2016 |
|
RU2789884C2 |
| ANTI-HLA-G ANTIBODIES AND THEIR USE | 2019 |
|
RU2797724C2 |
